Liver Cancer Diagnostics Market

Q: What will be the CAGR of the global liver cancer diagnostics industry during the forecast period?

The CAGR is anticipated to be 6.1% from 2025 to 2035 Read More

Liver Cancer Diagnostics Market (Diagnostic Test Type: Imaging Tests, Blood Tests, Biopsy and Genetic Biomarkers; Cancer Type: Hepatocellular Carcinoma (HCC), Cholangiocarcinoma, Angiosarcoma of the liver, and Others; and End-user: Hospital Laboratories, Diagnostic Centers, Academic and Research Institutes and Others) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025-2035

Liver Cancer Diagnostics Market Outlook

The global liver cancer diagnostics market size was valued at US$ 9.6 Bn in 2024 and is projected to reach US$ 18.4 Bn by 2035, expanding at a CAGR of 6.1% from 2025 to 2035. The market growth is driven by rising prevalence of liver cancer, ongoing advancements in diagnostic technologies, and increasing awareness and screening initiatives.

Market Size & Highlights

The liver cancer diagnostics market reached US$ 9.6 Bn in 2024.
It is expected to climb to US$ 18.4 Bn by 2035.
The industry is anticipated to expand at a CAGR of 6.1% from 2025 to 2035.
Top companies in the liver cancer diagnostics industry include F. Hoffmann-La Roche AG, Bio-Rad Laboratories, Inc., Agilent Technologies Inc., and Siemens Healthineers AG
North America dominated the market in 2024, holding the largest revenue share of 41.3%.
By Diagnostic Test Type, the Blood Tests segment held the major market share of 32.1% in 2024.

Liver Cancer Diagnostics Market By Revenue

Analysts’ Viewpoint regarding Liver Cancer Diagnostics Market

Strengthening healthcare facilities and expansion of public health screening programs are significant drivers of liver cancer diagnostics market. Enhanced laboratory networks and enhanced access to tertiary care centers in the form of public-private partnerships and strategic financial planning enhance diagnostic volumes and test uptake. Enhanced education of clinicians and guideline-based surveillance of high-risk groups boost referral volumes and market demand.

Supportive reimbursement models and the inclusion of diagnostic tests in national health benefit packages have helped check expenditures and facilitated easy adoption, hence forming the basis for consistent market growth. Capacity-building programs, including specialized training of pathologists and radiologists, raise the quality of diagnostics.

Private equity, venture capital, and institutional investment drive market growth through financing commercialization and business expansion. Centralized lab models and contract manufacturing enable economies of scale driving price optimization and provide improved market penetration.

Regulatory transparencies such as aligned submission routes and conditional approvals across regions shorten time-to-market and commercial risk. Complementary budget incentives, grants, and the other favorable tax regimes in some areas also lower risk and build capacity.

The use of liquid biopsy methods, AI-assisted image analysis, and minimally invasive sampling for clinical pathways is setting new standards and making detections at an early stage during regular check-ups. In order to achieve quicker turnaround times as well as provide access to clinicians from remote locations, the companies are installing data platforms that are interoperable with technology, tele-diagnostic services, and cloud-based reporting.

Real-world evidence, multi-center validation studies along with registry data, are the main features on which the industry is banking for having fruitful payer discussions and thus positioning of value-based negotiations in reimbursement. Therefore, collaborations amongst diagnostics providers, hospitals, and payers are becoming more widespread as they reside new care models and evidence-generation initiatives.

The competitive environment is dominated by the formation of strategic alliances, portfolio diversification, and service-led differentiation rather than depending on single-test offerings.

Liver Cancer Diagnostics Market Introduction

Liver cancer diagnostics refers to the variety of medical examinations and technologies applied to identify, authenticate, and monitor liver cancer. In this case, it is the most widespread form, the hepatocellular carcinoma. The process starts with the determination of individuals at risk, for example, those patients with chronic liver disease, hepatitis B or C infection, or cirrhosis. Primary assessments commonly involve screening for liver function and identification of high concentrations of biomarkers that can indicate the development of cancer or tumor growth.

Imaging studies are important in the diagnosis of liver cancer, providing non-invasive techniques of detecting and visualizing the presence and character of a tumor. Imaging studies using ultrasound, CT, and MRI may assess tumor size, number, and site. Imaging with contrast agent-enhanced uptake improves sensitivity to tumor detection and staging, thereby enabling physicians to deduce the suitable treatment approach.

Diagnosing through blood tests is important, particularly tests measuring alpha-fetoprotein (AFP) and the other emerging biomarkers. The use of such biochemical markers provides early diagnosis, prognosis, and treatment monitoring of cancer, especially when results from imaging techniques are not conclusive.

Attribute	Detail
Liver Cancer Diagnostics Market Drivers	Rising Incidence of Liver Cancer Innovations in Diagnostic Techniques

Rising Incidence of Liver Cancer Skyrocketing the Liver Cancer Diagnostics Market Share

The rising prevalence of liver cancer is propelling the liver cancer diagnostics market. As liver cancer has been epidemically spreading across the globe, providers of health services are obliged to set up comprehensive screening programs for the risk groups. The early identification of tumors will lead to provision of timely intervention, which will then result in the effectiveness of patient outcomes.

Moreover, the rise in liver cancer cases is a major factor that is driving the development of healthcare infrastructure, mainly the facilities for specialized imaging and diagnostic labs. It is quite interesting that the capabilities of the diagnostic centers and hospitals are being elevated to allow more patient admissions, which is another facet of the situation that is indirectly leading to the demand for advanced diagnostic technology.

Such a move not only provides for the early diagnosis of the disease but also makes it possible to keep the patients under continuous observation, thus consolidating the expansion.

Moreover, the higher incidence of the disease is leading the healthcare systems and policymakers to include liver cancer diagnostics in their care protocols.

In conclusion, a higher disease burden scenario impels the research and development sector to focus on the necessity for accurate and scalable diagnostics. The companies are motivated to develop more sensitive assays, giving more detection accuracy, and making the workflow more efficient. The collaboration between diagnostic providers, healthcare institutions, and public health agencies aim to address unmet clinical needs, driving innovation reinforcing market diversification.

Innovations in Diagnostic Techniques is Fostering Liver Cancer Diagnostics Market Share

Advancements in diagnostic techniques lead to better accuracy, efficiency, and patient care, which is a significant factor that contributes in propelling the liver cancer diagnostics market. Such diagnostics have paved the way for early detection of liver cancer through the use of contrast-enhanced MRI, multiphase CT scans, and elastography. These technological advancements reduce errors in diagnosis and give clinicians the opportunity to select the most suitable therapies, hence there is an increased application of diagnostic products in hospitals.

Primary biomarker and molecular-based test platforms have transformed liver cancer diagnosis to a new level of ease through the use of considerably less invasive methods instead of traditional biopsies. Liquid biopsy, circulating tumor DNA sequencing, and multi-marker blood panels not only facilitate early detection but also allow for continuous monitoring of the disease and provide targeted treatment options. They improve the diagnostic footprint, engage healthcare professionals, and create market demand by providing improved clinical utility over the current methods.

Some of the major factors that substantially increase the market share include integration of AI and machine learning in diagnostic workflows. AI-powered image analysis, automated reporting, and predictive algorithms are the main pillars of AI, not only reducing interpretation errors but also shortening turnaround times while optimizing clinical decision-making.

Besides, advancements in point-of-care testing and portable imaging devices are making liver cancer diagnostics available even in areas with limited resources.

Blood Tests Leading Global Liver Cancer Diagnostics Market

Liver Cancer Diagnostics Market By Type

Blood tests are the leading segment in liver cancer diagnostics, as these tests are less invasive, cheaper, and can be used repeatedly to check the disease progression. One of the biomarkers, such as alpha-fetoprotein (AFP), offers significant information for early detection, prediction, and treatment, thus making blood-based assays a favorable option among clinicians and patients.

Moreover, blood tests are instrumental in implementing large-scale screening programs and are used in usual monitoring of high-risk group patients. They also provide quick results, combine with modern molecular assays, and thus complement imaging techniques, which together contribute to their dominating position in the liver cancer diagnostics market.

Regional Outlook of Liver Cancer Diagnostics Market

Liver Cancer Diagnostics Market By Region

Attribute	Detail
Leading Region	North America

As per the latest liver cancer diagnostics market analysis, North America dominated in 2024, capturing a market share of 41.3%. Such an occurrence is mainly attributed to the region's strong healthcare system, high level of public knowledge of liver cancer, and frequent utilization of advanced diagnostic methods. Besides that, the presence of top-notch hospitals, highly qualified laboratories, and high performance screening programs, are factors that localize the early stages of the disease and its accurate follow-up, hence, are contributing to the market growth.

Moreover, the considerable government support, favorable reimbursement policies, and significant research funds accelerate the development of novel diagnostic solutions. The strategic collaborations between the public and private sectors and vast clinical research networks have become instrumental in consolidating the market's position, thereby ensuring adoption of advanced tests, biomarkers, and imaging modalities thus safeguarding North America's continued dominance over the global market.

Analysis of Key Players in Liver Cancer Diagnostics Market

The prominent companies leading the liver cancer diagnostics market are restructuring their tactical maneuvers chiefly around collaborations, extending their product range, and embracing new technology. These corporations are doing a variety of significant moves, such as the launch of advanced biomarker assays, widening point-of-care and imaging services, investing in AI-powered diagnostics, clinically validating their products more rigorously, and promoting activities to create awareness for early detection and thus, quicker market penetration globally.

F. Hoffmann-La Roche AG, AdvaCare Pharma, Siemens Healthineers AG, QIAGEN, Bio-Rad Laboratories, Inc., Agilent Technologies Inc., Atlas Medical GmbH, Epigenomics AG, GE HealthCare, Koninklijke Philips N.V, CANON MEDICAL SYSTEMS CORPORATION, Samsung Medison Co., Ltd., Hipro Biotechnology Co.,Ltd., Mursla Ltd. / Mursla Inc., Exact Sciences Corporation, and Helio Genomics are some of the leading players operating in the global liver cancer diagnostics market.

Each of these players has been profiled in the liver cancer diagnostics market research report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Key Developments in Liver Cancer Diagnostics Market

In June 2025, Mursla Bio. announced that the FDA had granted breakthrough device designation to the EvoLiver test for hepatocellular carcinoma (HCC) surveillance among high-risk cirrhosis patients. The EvoLiver test would separate organ-specific hepatocyte EVs from blood with enrichment such that fewer than 10 microRNAs and proteins would be quantitated as HCC biomarker signatures.
In April 2025, scientists at Wuhan Union Hospital, through the development of a new immunoPET tracer, 68Ga-aGPC3-scFv (XH06), were able to show that it could detect hepatocellular carcinoma (HCC) with high sensitivity and specificity, even in the case of tumours less than one centimetre in size. The first-in-class molecular imaging agent targeting glypican-3 (GPC3) is a potential bright diagnostic and staging instrument for HCC, a major contributor to the death of cancer patients worldwide.

Liver Cancer Diagnostics Market Snapshot

Attribute	Detail
Size in 2024	US$ 9.6 Bn
Forecast Value in 2035	US$ 18.4 Bn
CAGR	6.1%
Forecast Period	2025-2035
Historical Data Available for	2020-2023
Quantitative Units	US$ Bn
Liver Cancer Diagnostics Market Analysis	It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, value chain analysis, and key trend analysis.
Competition Landscape	Competition Matrix Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format	Electronic (PDF) + Excel
Segmentation	Diagnostic Test Type Imaging Tests Ultrasound Computed tomography (CT) Magnetic resonance imaging (MRI) Others (Bone scan, etc.) Blood Tests Alpha-fetoprotein blood (AFP) test Liver function tests (LFTs) Blood clotting tests Others (Kidney function tests, etc.) Biopsy Needle biopsy Laparoscopic biopsy Surgical biopsy Genetic Biomarkers miR-122 and miR-21 TP53 Other Genetic Biomarkers (CTNNB1, etc.) Cancer Type Hepatocellular carcinoma (HCC) Cholangiocarcinoma Angiosarcoma of the liver Others (Hepatoblastoma, etc.) End-user Hospital Laboratories Diagnostic Centers Academic and Research Institutes Others (Imaging Centers, etc.)
Regions Covered	North America Europe Asia Pacific Latin America Middle East & Africa
Countries Covered	U.S. Canada Germany U.K. France Italy Spain The Netherlands China Australia India Japan South Korea ASEAN Brazil Mexico Argentina GCC Countries South Africa
Companies Profiled	F. Hoffmann-La Roche AG AdvaCare Pharma Siemens Healthineers AG QIAGEN Bio-Rad Laboratories, Inc. Agilent Technologies Inc. Atlas Medical GmbH Epigenomics AG GE HealthCare Koninklijke Philips N.V CANON MEDICAL SYSTEMS CORPORATION Samsung Medison Co., Ltd. Hipro Biotechnology Co., Ltd. Mursla Ltd. / Mursla Inc. Exact Sciences Corporation Helio Genomics
Customization Scope	Available upon request
Pricing	Available upon request

Frequently Asked Questions

How big was the global liver cancer diagnostics market in 2024?

The global liver cancer diagnostics market was valued at US$ 9.6 Bn in 2024

How big will the global liver cancer diagnostics industry be in 2035?

The global liver cancer diagnostics industry is projected to reach more than US$ 18.4 Bn by the end of 2035

What are the factors driving the liver cancer diagnostics market?

The rising incidence of liver cancer, advances in diagnostic technologies like liquid biopsies and AI-powered imaging, increasing global awareness and screening initiatives, and factors such as the growing prevalence of risk factors like hepatitis and obesity, are some of the factors driving the expansion of liver cancer diagnostics market.

What will be the CAGR of the global liver cancer diagnostics industry during the forecast period?

The CAGR is anticipated to be 6.1% from 2025 to 2035

Who are the prominent players in the global liver cancer diagnostics market?

F. Hoffmann-La Roche Ltd, AdvaCare Pharma, Siemens Healthineers AG, QIAGEN, Bio-Rad Laboratories, Inc., Agilent Technologies Inc., Atlas Medical GmbH, Epigenomics AG, GE HealthCare, Koninklijke Philips N.V, CANON MEDICAL SYSTEMS CORPORATION, Samsung Medison Co., Ltd., Hipro Biotechnology Co.,Ltd., Mursla Ltd. / Mursla Inc., Exact Sciences Corporation, and Helio Genomics

Preface
- Market Definition and Scope
- Market Segmentation
- Key Research Objectives
- Research Highlights
Assumptions and Research Methodology
Executive Summary: Global Liver Cancer Diagnostics Market
Market Overview
- Introduction
  - Segment Definition
- Overview
- Market Dynamics
  - Drivers
  - Restraints
  - Opportunities
- Global Liver Cancer Diagnostics Market Analysis and Forecast, 2020-2035
  - Market Revenue Projections (US$ Bn)
Key Insights
- Healthcare Expenditure across Key Countries / Regions
- Recent Advancements in Liver Cancer Diagnostics
- Pricing Analysis of Liver Cancer Diagnostics
- Regulatory Scenario across Key Regions / Countries
- Reimbursement Landscape across Key Regions / Countries
- PORTER’s Five Forces Analysis
- PESTLE Analysis
- Go-to-Market Strategy for New Market Entrants
- Key Purchase Metrics for End-users
- Key Industry Events (Partnership, Collaborations, Product approvals, merger & acquisitions)
- Benchmarking of the Products Offered by the Leading Competitors
Global Liver Cancer Diagnostics Market Analysis and Forecast, by Diagnostic Test Type
- Introduction & Definition
- Key Findings/Developments
- Market Value Forecast, by Diagnostic Test Type, 2020-2035
  - Imaging Tests
    - Ultrasound
    - Computed tomography (CT)
    - Magnetic resonance imaging (MRI)
    - Others
  - Blood tests
    - Alpha-fetoprotein blood (AFP) test
    - Liver function tests (LFTs)
    - Blood clotting tests
    - Others
  - Biopsy
    - Needle biopsy
    - Laparoscopic biopsy
    - Surgical biopsy
  - Genetic Biomarkers
    - miR-122 and miR-21
    - TP53
    - Other Genetic Biomarkers
- Market Attractiveness Analysis, by Diagnostic Test Type
Global Liver Cancer Diagnostics Market Analysis and Forecast, by Cancer Type
- Introduction & Definition
- Key Findings/Developments
- Market Value Forecast, by Cancer Type, 2020-2035
  - Hepatocellular carcinoma (HCC)
  - Cholangiocarcinoma
  - Angiosarcoma of the liver
  - Others
- Market Attractiveness Analysis, by Cancer Type
Global Liver Cancer Diagnostics Market Analysis and Forecast, by End-user
- Introduction & Definition
- Key Findings/Developments
- Market Value Forecast, by End-user, 2020-2035
  - Hospital Laboratories
  - Diagnostic Centers
  - Academic and Research Institutes
  - Others
- Market Attractiveness Analysis, by End-user
Global Liver Cancer Diagnostics Market Analysis and Forecast, by Region
- Key Findings
- Market Value Forecast, by Region, 2020-2035
  - North America
  - Europe
  - Asia Pacific
  - Latin America
  - Middle East & Africa
- Market Attractiveness Analysis, by Region
North America Liver Cancer Diagnostics Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Diagnostic Test Type, 2020-2035
  - Imaging Tests
    - Ultrasound
    - Computed tomography (CT)
    - Magnetic resonance imaging (MRI)
    - Others
  - Blood tests
    - Alpha-fetoprotein blood (AFP) test
    - Liver function tests (LFTs)
    - Blood clotting tests
    - Others
  - Biopsy
    - Needle biopsy
    - Laparoscopic biopsy
    - Surgical biopsy
  - Genetic Biomarkers
    - miR-122 and miR-21
    - TP53
    - Other Genetic Biomarkers
- Market Value Forecast, by Cancer Type, 2020-2035
  - Hepatocellular carcinoma (HCC)
  - Cholangiocarcinoma
  - Angiosarcoma of the liver
  - Others
- Market Value Forecast, by End-user, 2020-2035
  - Hospital Laboratories
  - Diagnostic Centers
  - Academic and Research Institutes
  - Others
- Market Value Forecast, by Country, 2020-2035
  - U.S.
  - Canada
- Market Attractiveness Analysis
  - By Diagnostic Test Type
  - By Cancer Type
  - By End-user
  - By Country
U.S. Liver Cancer Diagnostics Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Diagnostic Test Type, 2020-2035
  - Imaging Tests
    - Ultrasound
    - Computed tomography (CT)
    - Magnetic resonance imaging (MRI)
    - Others
  - Blood tests
    - Alpha-fetoprotein blood (AFP) test
    - Liver function tests (LFTs)
    - Blood clotting tests
    - Others
  - Biopsy
    - Needle biopsy
    - Laparoscopic biopsy
    - Surgical biopsy
  - Genetic Biomarkers
    - miR-122 and miR-21
    - TP53
    - Other Genetic Biomarkers
- Market Value Forecast, by Cancer Type, 2020-2035
  - Hepatocellular carcinoma (HCC)
  - Cholangiocarcinoma
  - Angiosarcoma of the liver
  - Others
- Market Value Forecast, by End-user, 2020-2035
  - Hospital Laboratories
  - Diagnostic Centers
  - Academic and Research Institutes
  - Others
- Market Attractiveness Analysis
  - By Diagnostic Test Type
  - By Cancer Type
  - By End-user
Canada Liver Cancer Diagnostics Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Diagnostic Test Type, 2020-2035
  - Imaging Tests
    - Ultrasound
    - Computed tomography (CT)
    - Magnetic resonance imaging (MRI)
    - Others
  - Blood tests
    - Alpha-fetoprotein blood (AFP) test
    - Liver function tests (LFTs)
    - Blood clotting tests
    - Others
  - Biopsy
    - Needle biopsy
    - Laparoscopic biopsy
    - Surgical biopsy
  - Genetic Biomarkers
    - miR-122 and miR-21
    - TP53
    - Other Genetic Biomarkers
- Market Value Forecast, by Cancer Type, 2020-2035
  - Hepatocellular carcinoma (HCC)
  - Cholangiocarcinoma
  - Angiosarcoma of the liver
  - Others
- Market Value Forecast, by End-user, 2020-2035
  - Hospital Laboratories
  - Diagnostic Centers
  - Academic and Research Institutes
  - Others
- Market Attractiveness Analysis
  - By Diagnostic Test Type
  - By Cancer Type
  - By End-user
Europe Liver Cancer Diagnostics Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Diagnostic Test Type, 2020-2035
  - Imaging Tests
    - Ultrasound
    - Computed tomography (CT)
    - Magnetic resonance imaging (MRI)
    - Others
  - Blood tests
    - Alpha-fetoprotein blood (AFP) test
    - Liver function tests (LFTs)
    - Blood clotting tests
    - Others
  - Biopsy
    - Needle biopsy
    - Laparoscopic biopsy
    - Surgical biopsy
  - Genetic Biomarkers
    - miR-122 and miR-21
    - TP53
    - Other Genetic Biomarkers
- Market Value Forecast, by Cancer Type, 2020-2035
  - Hepatocellular carcinoma (HCC)
  - Cholangiocarcinoma
  - Angiosarcoma of the liver
  - Others
- Market Value Forecast, by End-user, 2020-2035
  - Hospital Laboratories
  - Diagnostic Centers
  - Academic and Research Institutes
  - Others
- Market Value Forecast, by Country/Sub-region, 2020-2035
  - Germany
  - UK
  - France
  - Italy
  - Spain
  - The Netherlands
  - Rest of Europe
- Market Attractiveness Analysis
  - By Diagnostic Test Type
  - By Cancer Type
  - By End-user
  - By Country/Sub-region
Germany Liver Cancer Diagnostics Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Diagnostic Test Type, 2020-2035
  - Imaging Tests
    - Ultrasound
    - Computed tomography (CT)
    - Magnetic resonance imaging (MRI)
    - Others
  - Blood tests
    - Alpha-fetoprotein blood (AFP) test
    - Liver function tests (LFTs)
    - Blood clotting tests
    - Others
  - Biopsy
    - Needle biopsy
    - Laparoscopic biopsy
    - Surgical biopsy
  - Genetic Biomarkers
    - miR-122 and miR-21
    - TP53
    - Other Genetic Biomarkers
- Market Value Forecast, by Cancer Type, 2020-2035
  - Hepatocellular carcinoma (HCC)
  - Cholangiocarcinoma
  - Angiosarcoma of the liver
  - Others
- Market Value Forecast, by End-user, 2020-2035
  - Hospital Laboratories
  - Diagnostic Centers
  - Academic and Research Institutes
  - Others
- Market Attractiveness Analysis
  - By Diagnostic Test Type
  - By Cancer Type
  - By End-user
UK Liver Cancer Diagnostics Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Diagnostic Test Type, 2020-2035
  - Imaging Tests
    - Ultrasound
    - Computed tomography (CT)
    - Magnetic resonance imaging (MRI)
    - Others
  - Blood tests
    - Alpha-fetoprotein blood (AFP) test
    - Liver function tests (LFTs)
    - Blood clotting tests
    - Others
  - Biopsy
    - Needle biopsy
    - Laparoscopic biopsy
    - Surgical biopsy
  - Genetic Biomarkers
    - miR-122 and miR-21
    - TP53
    - Other Genetic Biomarkers
- Market Value Forecast, by Cancer Type, 2020-2035
  - Hepatocellular carcinoma (HCC)
  - Cholangiocarcinoma
  - Angiosarcoma of the liver
  - Others
- Market Value Forecast, by End-user, 2020-2035
  - Hospital Laboratories
  - Diagnostic Centers
  - Academic and Research Institutes
  - Others
- Market Attractiveness Analysis
  - By Diagnostic Test Type
  - By Cancer Type
  - By End-user
France Liver Cancer Diagnostics Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Diagnostic Test Type, 2020-2035
  - Imaging Tests
    - Ultrasound
    - Computed tomography (CT)
    - Magnetic resonance imaging (MRI)
    - Others
  - Blood tests
    - Alpha-fetoprotein blood (AFP) test
    - Liver function tests (LFTs)
    - Blood clotting tests
    - Others
  - Biopsy
    - Needle biopsy
    - Laparoscopic biopsy
    - Surgical biopsy
  - Genetic Biomarkers
    - miR-122 and miR-21
    - TP53
    - Other Genetic Biomarkers
- Market Value Forecast, by Cancer Type, 2020-2035
  - Hepatocellular carcinoma (HCC)
  - Cholangiocarcinoma
  - Angiosarcoma of the liver
  - Others
- Market Value Forecast, by End-user, 2020-2035
  - Hospital Laboratories
  - Diagnostic Centers
  - Academic and Research Institutes
  - Others
- Market Attractiveness Analysis
  - By Diagnostic Test Type
  - By Cancer Type
  - By End-user
Italy Liver Cancer Diagnostics Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Diagnostic Test Type, 2020-2035
  - Imaging Tests
    - Ultrasound
    - Computed tomography (CT)
    - Magnetic resonance imaging (MRI)
    - Others
  - Blood tests
    - Alpha-fetoprotein blood (AFP) test
    - Liver function tests (LFTs)
    - Blood clotting tests
    - Others
  - Biopsy
    - Needle biopsy
    - Laparoscopic biopsy
    - Surgical biopsy
  - Genetic Biomarkers
    - miR-122 and miR-21
    - TP53
    - Other Genetic Biomarkers
- Market Value Forecast, by Cancer Type, 2020-2035
  - Hepatocellular carcinoma (HCC)
  - Cholangiocarcinoma
  - Angiosarcoma of the liver
  - Others
- Market Value Forecast, by End-user, 2020-2035
  - Hospital Laboratories
  - Diagnostic Centers
  - Academic and Research Institutes
  - Others
- Market Attractiveness Analysis
  - By Diagnostic Test Type
  - By Cancer Type
  - By End-user
Spain Liver Cancer Diagnostics Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Diagnostic Test Type, 2020-2035
  - Imaging Tests
    - Ultrasound
    - Computed tomography (CT)
    - Magnetic resonance imaging (MRI)
    - Others
  - Blood tests
    - Alpha-fetoprotein blood (AFP) test
    - Liver function tests (LFTs)
    - Blood clotting tests
    - Others
  - Biopsy
    - Needle biopsy
    - Laparoscopic biopsy
    - Surgical biopsy
  - Genetic Biomarkers
    - miR-122 and miR-21
    - TP53
    - Other Genetic Biomarkers
- Market Value Forecast, by Cancer Type, 2020-2035
  - Hepatocellular carcinoma (HCC)
  - Cholangiocarcinoma
  - Angiosarcoma of the liver
  - Others
- Market Value Forecast, by End-user, 2020-2035
  - Hospital Laboratories
  - Diagnostic Centers
  - Academic and Research Institutes
  - Others
- Market Attractiveness Analysis
  - By Diagnostic Test Type
  - By Cancer Type
  - By End-user
The Netherlands Liver Cancer Diagnostics Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Diagnostic Test Type, 2020-2035
  - Imaging Tests
    - Ultrasound
    - Computed tomography (CT)
    - Magnetic resonance imaging (MRI)
    - Others
  - Blood tests
    - Alpha-fetoprotein blood (AFP) test
    - Liver function tests (LFTs)
    - Blood clotting tests
    - Others
  - Biopsy
    - Needle biopsy
    - Laparoscopic biopsy
    - Surgical biopsy
  - Genetic Biomarkers
    - miR-122 and miR-21
    - TP53
    - Other Genetic Biomarkers
- Market Value Forecast, by Cancer Type, 2020-2035
  - Hepatocellular carcinoma (HCC)
  - Cholangiocarcinoma
  - Angiosarcoma of the liver
  - Others
- Market Value Forecast, by End-user, 2020-2035
  - Hospital Laboratories
  - Diagnostic Centers
  - Academic and Research Institutes
  - Others
- Market Attractiveness Analysis
  - By Diagnostic Test Type
  - By Cancer Type
  - By End-user
Rest of Europe Liver Cancer Diagnostics Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Diagnostic Test Type, 2020-2035
  - Imaging Tests
    - Ultrasound
    - Computed tomography (CT)
    - Magnetic resonance imaging (MRI)
    - Others
  - Blood tests
    - Alpha-fetoprotein blood (AFP) test
    - Liver function tests (LFTs)
    - Blood clotting tests
    - Others
  - Biopsy
    - Needle biopsy
    - Laparoscopic biopsy
    - Surgical biopsy
  - Genetic Biomarkers
    - miR-122 and miR-21
    - TP53
    - Other Genetic Biomarkers
- Market Value Forecast, by Cancer Type, 2020-2035
  - Hepatocellular carcinoma (HCC)
  - Cholangiocarcinoma
  - Angiosarcoma of the liver
  - Others
- Market Value Forecast, by End-user, 2020-2035
  - Hospital Laboratories
  - Diagnostic Centers
  - Academic and Research Institutes
  - Others
- Market Attractiveness Analysis
  - By Diagnostic Test Type
  - By Cancer Type
  - By End-user
Asia Pacific Liver Cancer Diagnostics Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Diagnostic Test Type, 2020-2035
  - Imaging Tests
    - Ultrasound
    - Computed tomography (CT)
    - Magnetic resonance imaging (MRI)
    - Others
  - Blood tests
    - Alpha-fetoprotein blood (AFP) test
    - Liver function tests (LFTs)
    - Blood clotting tests
    - Others
  - Biopsy
    - Needle biopsy
    - Laparoscopic biopsy
    - Surgical biopsy
  - Genetic Biomarkers
    - miR-122 and miR-21
    - TP53
    - Other Genetic Biomarkers
- Market Value Forecast, by Cancer Type, 2020-2035
  - Hepatocellular carcinoma (HCC)
  - Cholangiocarcinoma
  - Angiosarcoma of the liver
  - Others
- Market Value Forecast, by End-user, 2020-2035
  - Hospital Laboratories
  - Diagnostic Centers
  - Academic and Research Institutes
  - Others
- Market Value Forecast, by Country/Sub-region, 2020-2035
  - China
  - India
  - Japan
  - South Korea
  - Australia & New Zealand
  - ASEAN
  - Rest of Asia Pacific
- Market Attractiveness Analysis
  - By Diagnostic Test Type
  - By Cancer Type
  - By End-user
  - By Country/Sub-region
China Liver Cancer Diagnostics Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Diagnostic Test Type, 2020-2035
  - Imaging Tests
    - Ultrasound
    - Computed tomography (CT)
    - Magnetic resonance imaging (MRI)
    - Others
  - Blood tests
    - Alpha-fetoprotein blood (AFP) test
    - Liver function tests (LFTs)
    - Blood clotting tests
    - Others
  - Biopsy
    - Needle biopsy
    - Laparoscopic biopsy
    - Surgical biopsy
  - Genetic Biomarkers
    - miR-122 and miR-21
    - TP53
    - Other Genetic Biomarkers
- Market Value Forecast, by Cancer Type, 2020-2035
  - Hepatocellular carcinoma (HCC)
  - Cholangiocarcinoma
  - Angiosarcoma of the liver
  - Others
- Market Value Forecast, by End-user, 2020-2035
  - Hospital Laboratories
  - Diagnostic Centers
  - Academic and Research Institutes
  - Others
- Market Attractiveness Analysis
  - By Diagnostic Test Type
  - By Cancer Type
  - By End-user
India Liver Cancer Diagnostics Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Diagnostic Test Type, 2020-2035
  - Imaging Tests
    - Ultrasound
    - Computed tomography (CT)
    - Magnetic resonance imaging (MRI)
    - Others
  - Blood tests
    - Alpha-fetoprotein blood (AFP) test
    - Liver function tests (LFTs)
    - Blood clotting tests
    - Others
  - Biopsy
    - Needle biopsy
    - Laparoscopic biopsy
    - Surgical biopsy
  - Genetic Biomarkers
    - miR-122 and miR-21
    - TP53
    - Other Genetic Biomarkers
- Market Value Forecast, by Cancer Type, 2020-2035
  - Hepatocellular carcinoma (HCC)
  - Cholangiocarcinoma
  - Angiosarcoma of the liver
  - Others
- Market Value Forecast, by End-user, 2020-2035
  - Hospital Laboratories
  - Diagnostic Centers
  - Academic and Research Institutes
  - Others
- Market Attractiveness Analysis
  - By Diagnostic Test Type
  - By Cancer Type
  - By End-user
Japan Liver Cancer Diagnostics Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Diagnostic Test Type, 2020-2035
  - Imaging Tests
    - Ultrasound
    - Computed tomography (CT)
    - Magnetic resonance imaging (MRI)
    - Others
  - Blood tests
    - Alpha-fetoprotein blood (AFP) test
    - Liver function tests (LFTs)
    - Blood clotting tests
    - Others
  - Biopsy
    - Needle biopsy
    - Laparoscopic biopsy
    - Surgical biopsy
  - Genetic Biomarkers
    - miR-122 and miR-21
    - TP53
    - Other Genetic Biomarkers
- Market Value Forecast, by Cancer Type, 2020-2035
  - Hepatocellular carcinoma (HCC)
  - Cholangiocarcinoma
  - Angiosarcoma of the liver
  - Others
- Market Value Forecast, by End-user, 2020-2035
  - Hospital Laboratories
  - Diagnostic Centers
  - Academic and Research Institutes
  - Others
- Market Attractiveness Analysis
  - By Diagnostic Test Type
  - By Cancer Type
  - By End-user
South Korea Liver Cancer Diagnostics Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Diagnostic Test Type, 2020-2035
  - Imaging Tests
    - Ultrasound
    - Computed tomography (CT)
    - Magnetic resonance imaging (MRI)
    - Others
  - Blood tests
    - Alpha-fetoprotein blood (AFP) test
    - Liver function tests (LFTs)
    - Blood clotting tests
    - Others
  - Biopsy
    - Needle biopsy
    - Laparoscopic biopsy
    - Surgical biopsy
  - Genetic Biomarkers
    - miR-122 and miR-21
    - TP53
    - Other Genetic Biomarkers
- Market Value Forecast, by Cancer Type, 2020-2035
  - Hepatocellular carcinoma (HCC)
  - Cholangiocarcinoma
  - Angiosarcoma of the liver
  - Others
- Market Value Forecast, by End-user, 2020-2035
  - Hospital Laboratories
  - Diagnostic Centers
  - Academic and Research Institutes
  - Others
- Market Attractiveness Analysis
  - By Diagnostic Test Type
  - By Cancer Type
  - By End-user
Australia & New Zealand Liver Cancer Diagnostics Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Diagnostic Test Type, 2020-2035
  - Imaging Tests
    - Ultrasound
    - Computed tomography (CT)
    - Magnetic resonance imaging (MRI)
    - Others
  - Blood tests
    - Alpha-fetoprotein blood (AFP) test
    - Liver function tests (LFTs)
    - Blood clotting tests
    - Others
  - Biopsy
    - Needle biopsy
    - Laparoscopic biopsy
    - Surgical biopsy
  - Genetic Biomarkers
    - miR-122 and miR-21
    - TP53
    - Other Genetic Biomarkers
- Market Value Forecast, by Cancer Type, 2020-2035
  - Hepatocellular carcinoma (HCC)
  - Cholangiocarcinoma
  - Angiosarcoma of the liver
  - Others
- Market Value Forecast, by End-user, 2020-2035
  - Hospital Laboratories
  - Diagnostic Centers
  - Academic and Research Institutes
  - Others
- Market Attractiveness Analysis
  - By Diagnostic Test Type
  - By Cancer Type
  - By End-user
ASEAN Liver Cancer Diagnostics Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Diagnostic Test Type, 2020-2035
  - Imaging Tests
    - Ultrasound
    - Computed tomography (CT)
    - Magnetic resonance imaging (MRI)
    - Others
  - Blood tests
    - Alpha-fetoprotein blood (AFP) test
    - Liver function tests (LFTs)
    - Blood clotting tests
    - Others
  - Biopsy
    - Needle biopsy
    - Laparoscopic biopsy
    - Surgical biopsy
  - Genetic Biomarkers
    - miR-122 and miR-21
    - TP53
    - Other Genetic Biomarkers
- Market Value Forecast, by Cancer Type, 2020-2035
  - Hepatocellular carcinoma (HCC)
  - Cholangiocarcinoma
  - Angiosarcoma of the liver
  - Others
- Market Value Forecast, by End-user, 2020-2035
  - Hospital Laboratories
  - Diagnostic Centers
  - Academic and Research Institutes
  - Others
- Market Attractiveness Analysis
  - By Diagnostic Test Type
  - By Cancer Type
  - By End-user
Rest of Asia Pacific Liver Cancer Diagnostics Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Diagnostic Test Type, 2020-2035
  - Imaging Tests
    - Ultrasound
    - Computed tomography (CT)
    - Magnetic resonance imaging (MRI)
    - Others
  - Blood tests
    - Alpha-fetoprotein blood (AFP) test
    - Liver function tests (LFTs)
    - Blood clotting tests
    - Others
  - Biopsy
    - Needle biopsy
    - Laparoscopic biopsy
    - Surgical biopsy
  - Genetic Biomarkers
    - miR-122 and miR-21
    - TP53
    - Other Genetic Biomarkers
- Market Value Forecast, by Cancer Type, 2020-2035
  - Hepatocellular carcinoma (HCC)
  - Cholangiocarcinoma
  - Angiosarcoma of the liver
  - Others
- Market Value Forecast, by End-user, 2020-2035
  - Hospital Laboratories
  - Diagnostic Centers
  - Academic and Research Institutes
  - Others
- Market Attractiveness Analysis
  - By Diagnostic Test Type
  - By Cancer Type
  - By End-user
Latin America Liver Cancer Diagnostics Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Diagnostic Test Type, 2020-2035
  - Imaging Tests
    - Ultrasound
    - Computed tomography (CT)
    - Magnetic resonance imaging (MRI)
    - Others
  - Blood tests
    - Alpha-fetoprotein blood (AFP) test
    - Liver function tests (LFTs)
    - Blood clotting tests
    - Others
  - Biopsy
    - Needle biopsy
    - Laparoscopic biopsy
    - Surgical biopsy
  - Genetic Biomarkers
    - miR-122 and miR-21
    - TP53
    - Other Genetic Biomarkers
- Market Value Forecast, by Cancer Type, 2020-2035
  - Hepatocellular carcinoma (HCC)
  - Cholangiocarcinoma
  - Angiosarcoma of the liver
  - Others
- Market Value Forecast, by End-user, 2020-2035
  - Hospital Laboratories
  - Diagnostic Centers
  - Academic and Research Institutes
  - Others
- Market Value Forecast, by Country/Sub-region, 2020-2035
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
- Market Attractiveness Analysis
  - By Diagnostic Test Type
  - By Cancer Type
  - By End-user
  - By Country/Sub-region
Brazil Liver Cancer Diagnostics Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Diagnostic Test Type, 2020-2035
  - Imaging Tests
    - Ultrasound
    - Computed tomography (CT)
    - Magnetic resonance imaging (MRI)
    - Others
  - Blood tests
    - Alpha-fetoprotein blood (AFP) test
    - Liver function tests (LFTs)
    - Blood clotting tests
    - Others
  - Biopsy
    - Needle biopsy
    - Laparoscopic biopsy
    - Surgical biopsy
  - Genetic Biomarkers
    - miR-122 and miR-21
    - TP53
    - Other Genetic Biomarkers
- Market Value Forecast, by Cancer Type, 2020-2035
  - Hepatocellular carcinoma (HCC)
  - Cholangiocarcinoma
  - Angiosarcoma of the liver
  - Others
- Market Value Forecast, by End-user, 2020-2035
  - Hospital Laboratories
  - Diagnostic Centers
  - Academic and Research Institutes
  - Others
- Market Attractiveness Analysis
  - By Diagnostic Test Type
  - By Cancer Type
  - By End-user
Argentina Liver Cancer Diagnostics Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Diagnostic Test Type, 2020-2035
  - Imaging Tests
    - Ultrasound
    - Computed tomography (CT)
    - Magnetic resonance imaging (MRI)
    - Others
  - Blood tests
    - Alpha-fetoprotein blood (AFP) test
    - Liver function tests (LFTs)
    - Blood clotting tests
    - Others
  - Biopsy
    - Needle biopsy
    - Laparoscopic biopsy
    - Surgical biopsy
  - Genetic Biomarkers
    - miR-122 and miR-21
    - TP53
    - Other Genetic Biomarkers
- Market Value Forecast, by Cancer Type, 2020-2035
  - Hepatocellular carcinoma (HCC)
  - Cholangiocarcinoma
  - Angiosarcoma of the liver
  - Others
- Market Value Forecast, by End-user, 2020-2035
  - Hospital Laboratories
  - Diagnostic Centers
  - Academic and Research Institutes
  - Others
- Market Attractiveness Analysis
  - By Diagnostic Test Type
  - By Cancer Type
  - By End-user
Mexico Liver Cancer Diagnostics Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Diagnostic Test Type, 2020-2035
  - Imaging Tests
    - Ultrasound
    - Computed tomography (CT)
    - Magnetic resonance imaging (MRI)
    - Others
  - Blood tests
    - Alpha-fetoprotein blood (AFP) test
    - Liver function tests (LFTs)
    - Blood clotting tests
    - Others
  - Biopsy
    - Needle biopsy
    - Laparoscopic biopsy
    - Surgical biopsy
  - Genetic Biomarkers
    - miR-122 and miR-21
    - TP53
    - Other Genetic Biomarkers
- Market Value Forecast, by Cancer Type, 2020-2035
  - Hepatocellular carcinoma (HCC)
  - Cholangiocarcinoma
  - Angiosarcoma of the liver
  - Others
- Market Value Forecast, by End-user, 2020-2035
  - Hospital Laboratories
  - Diagnostic Centers
  - Academic and Research Institutes
  - Others
- Market Attractiveness Analysis
  - By Diagnostic Test Type
  - By Cancer Type
  - By End-user
Rest of Latin America Liver Cancer Diagnostics Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Diagnostic Test Type, 2020-2035
  - Imaging Tests
    - Ultrasound
    - Computed tomography (CT)
    - Magnetic resonance imaging (MRI)
    - Others
  - Blood tests
    - Alpha-fetoprotein blood (AFP) test
    - Liver function tests (LFTs)
    - Blood clotting tests
    - Others
  - Biopsy
    - Needle biopsy
    - Laparoscopic biopsy
    - Surgical biopsy
  - Genetic Biomarkers
    - miR-122 and miR-21
    - TP53
    - Other Genetic Biomarkers
- Market Value Forecast, by Cancer Type, 2020-2035
  - Hepatocellular carcinoma (HCC)
  - Cholangiocarcinoma
  - Angiosarcoma of the liver
  - Others
- Market Value Forecast, by End-user, 2020-2035
  - Hospital Laboratories
  - Diagnostic Centers
  - Academic and Research Institutes
  - Others
- Market Attractiveness Analysis
  - By Diagnostic Test Type
  - By Cancer Type
  - By End-user
Middle East & Africa Liver Cancer Diagnostics Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Diagnostic Test Type, 2020-2035
  - Imaging Tests
    - Ultrasound
    - Computed tomography (CT)
    - Magnetic resonance imaging (MRI)
    - Others
  - Blood tests
    - Alpha-fetoprotein blood (AFP) test
    - Liver function tests (LFTs)
    - Blood clotting tests
    - Others
  - Biopsy
    - Needle biopsy
    - Laparoscopic biopsy
    - Surgical biopsy
  - Genetic Biomarkers
    - miR-122 and miR-21
    - TP53
    - Other Genetic Biomarkers
- Market Value Forecast, by Cancer Type, 2020-2035
  - Hepatocellular carcinoma (HCC)
  - Cholangiocarcinoma
  - Angiosarcoma of the liver
  - Others
- Market Value Forecast, by End-user, 2020-2035
  - Hospital Laboratories
  - Diagnostic Centers
  - Academic and Research Institutes
  - Others
- Market Value Forecast, by Country/Sub-region, 2020-2035
  - GCC Countries
  - South Africa
  - Rest of Middle East & Africa
- Market Attractiveness Analysis
  - By Diagnostic Test Type
  - By Cancer Type
  - By End-user
  - By Country/Sub-region
GCC Countries Liver Cancer Diagnostics Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Diagnostic Test Type, 2020-2035
  - Imaging Tests
    - Ultrasound
    - Computed tomography (CT)
    - Magnetic resonance imaging (MRI)
    - Others
  - Blood tests
    - Alpha-fetoprotein blood (AFP) test
    - Liver function tests (LFTs)
    - Blood clotting tests
    - Others
  - Biopsy
    - Needle biopsy
    - Laparoscopic biopsy
    - Surgical biopsy
  - Genetic Biomarkers
    - miR-122 and miR-21
    - TP53
    - Other Genetic Biomarkers
- Market Value Forecast, by Cancer Type, 2020-2035
  - Hepatocellular carcinoma (HCC)
  - Cholangiocarcinoma
  - Angiosarcoma of the liver
  - Others
- Market Value Forecast, by End-user, 2020-2035
  - Hospital Laboratories
  - Diagnostic Centers
  - Academic and Research Institutes
  - Others
- Market Attractiveness Analysis
  - By Diagnostic Test Type
  - By Cancer Type
  - By End-user
South Africa Liver Cancer Diagnostics Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Diagnostic Test Type, 2020-2035
  - Imaging Tests
    - Ultrasound
    - Computed tomography (CT)
    - Magnetic resonance imaging (MRI)
    - Others
  - Blood tests
    - Alpha-fetoprotein blood (AFP) test
    - Liver function tests (LFTs)
    - Blood clotting tests
    - Others
  - Biopsy
    - Needle biopsy
    - Laparoscopic biopsy
    - Surgical biopsy
  - Genetic Biomarkers
    - miR-122 and miR-21
    - TP53
    - Other Genetic Biomarkers
- Market Value Forecast, by Cancer Type, 2020-2035
  - Hepatocellular carcinoma (HCC)
  - Cholangiocarcinoma
  - Angiosarcoma of the liver
  - Others
- Market Value Forecast, by End-user, 2020-2035
  - Hospital Laboratories
  - Diagnostic Centers
  - Academic and Research Institutes
  - Others
- Market Attractiveness Analysis
  - By Diagnostic Test Type
  - By Cancer Type
  - By End-user
Rest of Middle East & Africa Liver Cancer Diagnostics Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Diagnostic Test Type, 2020-2035
  - Imaging Tests
    - Ultrasound
    - Computed tomography (CT)
    - Magnetic resonance imaging (MRI)
    - Others
  - Blood tests
    - Alpha-fetoprotein blood (AFP) test
    - Liver function tests (LFTs)
    - Blood clotting tests
    - Others
  - Biopsy
    - Needle biopsy
    - Laparoscopic biopsy
    - Surgical biopsy
  - Genetic Biomarkers
    - miR-122 and miR-21
    - TP53
    - Other Genetic Biomarkers
- Market Value Forecast, by Cancer Type, 2020-2035
  - Hepatocellular carcinoma (HCC)
  - Cholangiocarcinoma
  - Angiosarcoma of the liver
  - Others
- Market Value Forecast, by End-user, 2020-2035
  - Hospital Laboratories
  - Diagnostic Centers
  - Academic and Research Institutes
  - Others
- Market Attractiveness Analysis
  - By Diagnostic Test Type
  - By Cancer Type
  - By End-user
Competition Landscape
- Market Player - Competition Matrix (By Tier and Size of Companies)
- Market Share Analysis, by Company (2024)
- Company Profiles
  - F. Hoffmann-La Roche Ltd
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - AdvaCare Pharma
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - Siemens Healthineers AG
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - QIAGEN
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - Bio-Rad Laboratories, Inc.
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - Agilent Technologies Inc.
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - Atlas Medical GmbH
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - Epigenomics AG
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - GE HealthCare
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - Koninklijke Philips N.V
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - CANON MEDICAL SYSTEMS CORPORATION
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - Samsung Medison Co., Ltd.
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - Hipro Biotechnology Co.,Ltd.
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - Mursla Ltd. / Mursla Inc.
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - Exact Sciences Corporation
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - Helio Genomics
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - Other Prominent Players
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments

List of Tables

Table 01: Global Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 02: Global Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 03: Global Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 04: Global Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 05: Global Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 06: Global Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 07: Global Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 08: Global Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Region, 2020 to 2035
Table 09: North America Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, by Country, 2020-2035
Table 10: North America Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 11: North America Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 12: North America Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 13: North America Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 14: North America Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 15: North America Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 16: North America Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 17: U.S. Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 18: U.S. Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 19: U.S. Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 20: U.S. Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 21: U.S. Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 22: U.S. Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 23: U.S. Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 24: Canada Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 25: Canada Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 26: Canada Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 27: Canada Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 28: Canada Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 29: Canada Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 30: Canada Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 31: Europe Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020-2035
Table 32: Europe Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 33: Europe Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 34: Europe Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 35: Europe Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 36: Europe Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 37: Europe Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 38: Europe Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 39: Germany Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 40: Germany Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 41: Germany Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 42: Germany Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 43: Germany Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 44: Germany Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 45: Germany Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 46: U.K. Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 47: U.K. Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 48: U.K. Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 49: U.K. Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 50: U.K. Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 51: U.K. Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 52: U.K. Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 53: France Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 54: France Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 55: France Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 56: France Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 57: France Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 58: France Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 59: France Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 60: Italy Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 61: Italy Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 62: Italy Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 63: Italy Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 64: Italy Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 65: Italy Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 66: Italy Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 67: Spain Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 68: Spain Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 69: Spain Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 70: Spain Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 71: Spain Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 72: Spain Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 73: Spain Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 74: Switzerland Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 75: Switzerland Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 76: Switzerland Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 77: Switzerland Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 78: Switzerland Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 79: Switzerland Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 80: Switzerland Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 81: The Netherlands Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 82: The Netherlands Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 83: The Netherlands Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 84: The Netherlands Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 85: The Netherlands Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 86: The Netherlands Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 87: The Netherlands Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 88: Rest of Europe Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 89: Rest of Europe Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 90: Rest of Europe Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 91: Rest of Europe Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 92: Rest of Europe Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 93: Rest of Europe Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 94: Rest of Europe Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 95: Asia Pacific Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020-2035
Table 96: Asia Pacific Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 97: Asia Pacific Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 98: Asia Pacific Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 99: Asia Pacific Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 100: Asia Pacific Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 101: Asia Pacific Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 102: Asia Pacific Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 103: China Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 104: China Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 105: China Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 106: China Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 107: China Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 108: China Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 109: China Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 110: India Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 111: India Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 112: India Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 113: India Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 114: India Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 115: India Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 116: India Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 117: Japan Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 118: Japan Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 119: Japan Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 120: Japan Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 121: Japan Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 122: Japan Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 123: Japan Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 124: South Korea Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 125: South Korea Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 126: South Korea Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 127: South Korea Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 128: South Korea Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 129: South Korea Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 130: South Korea Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 131: Australia & New Zealand Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 132: Australia & New Zealand Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 133: Australia & New Zealand Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 134: Australia & New Zealand Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 135: Australia & New Zealand Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 136: Australia & New Zealand Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 137: Australia & New Zealand Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 138: Rest of Asia Pacific Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 139: Rest of Asia Pacific Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 140: Rest of Asia Pacific Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 141: Rest of Asia Pacific Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 142: Rest of Asia Pacific Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 143: Rest of Asia Pacific Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 144: Rest of Asia Pacific Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 145: Latin America Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020-2035
Table 146: Latin America Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 147: Latin America Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 148: Latin America Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 149: Latin America Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 150: Latin America Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 151: Latin America Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 152: Latin America Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 153: Brazil Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 154: Brazil Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 155: Brazil Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 156: Brazil Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 157: Brazil Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 158: Brazil Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 159: Brazil Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 160: Mexico Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 161: Mexico Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 162: Mexico Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 163: Mexico Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 164: Mexico Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 165: Mexico Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 166: Mexico Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 167: Argentina Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 168: Argentina Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 169: Argentina Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 170: Argentina Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 171: Argentina Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 172: Argentina Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 173: Argentina Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 174: Rest of Latin America Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 175: Rest of Latin America Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 176: Rest of Latin America Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 177: Rest of Latin America Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 178: Rest of Latin America Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 179: Rest of Latin America Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 180: Rest of Latin America Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 181: Middle East & Africa Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020-2035
Table 182: Middle East & Africa Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 183: Middle East & Africa Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 184: Middle East & Africa Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 185: Middle East & Africa Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 186: Middle East & Africa Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 187: Middle East & Africa Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 188: Middle East & Africa Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 189: GCC Countries Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 190: GCC Countries Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 191: GCC Countries Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 192: GCC Countries Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 193: GCC Countries Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 194: GCC Countries Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 195: GCC Countries Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 196: South Africa Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 197: South Africa Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 198: South Africa Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 199: South Africa Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 200: South Africa Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 201: South Africa Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 202: South Africa Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 203: Rest of Middle East & Africa Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 204: Rest of Middle East & Africa Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 205: Rest of Middle East & Africa Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Blood Tests, 2020 to 2035
Table 206: Rest of Middle East & Africa Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Biopsy, 2020 to 2035
Table 207: Rest of Middle East & Africa Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Genetic Biomarkers, 2020 to 2035
Table 208: Rest of Middle East & Africa Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By Cancer Type, 2020 to 2035
Table 209: Rest of Middle East & Africa Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035

List of Figures

Figure 01: Global Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 02: Global Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 03: Global Liver Cancer Diagnostics Market Revenue (US$ Bn), by Imaging Tests, 2020 to 2035
Figure 04: Global Liver Cancer Diagnostics Market Revenue (US$ Bn), by Blood Tests, 2020 to 2035
Figure 05: Global Liver Cancer Diagnostics Market Revenue (US$ Bn), by Biopsy, 2020 to 2035
Figure 06: Global Liver Cancer Diagnostics Market Revenue (US$ Bn), by Genetic Biomarkers, 2020 to 2035
Figure 07: Global Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 08: Global Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 09: Global Liver Cancer Diagnostics Market Revenue (US$ Bn), by Hepatocellular carcinoma (HCC), 2020 to 2035
Figure 10: Global Liver Cancer Diagnostics Market Revenue (US$ Bn), by Cholangiocarcinoma, 2020 to 2035
Figure 11: Global Liver Cancer Diagnostics Market Revenue (US$ Bn), by Angiosarcoma of the liver, 2020 to 2035
Figure 12: Global Liver Cancer Diagnostics Market Revenue (US$ Bn), by Others, 2020 to 2035
Figure 13: Global Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 14: Global Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 15: Global Liver Cancer Diagnostics Market Revenue (US$ Bn), by Hospital Laboratories, 2020 to 2035
Figure 16: Global Liver Cancer Diagnostics Market Revenue (US$ Bn), by Diagnostic Centers, 2020 to 2035
Figure 17: Global Liver Cancer Diagnostics Market Revenue (US$ Bn), by Academic and Research Institutes, 2020 to 2035
Figure 18: Global Liver Cancer Diagnostics Market Revenue (US$ Bn), by Others, 2020 to 2035
Figure 19: Global Liver Cancer Diagnostics Market Value Share Analysis, By Region, 2024 and 2035
Figure 20: Global Liver Cancer Diagnostics Market Attractiveness Analysis, By Region, 2025 to 2035
Figure 21: North America Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 22: North America Liver Cancer Diagnostics Market Value Share Analysis, by Country, 2024 and 2035
Figure 23: North America Liver Cancer Diagnostics Market Attractiveness Analysis, by Country, 2025 to 2035
Figure 24: North America Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 25: North America Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 26: North America Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 27: North America Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 28: North America Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 29: North America Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 30: U.S. Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 31: U.S. Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 32: U.S. Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 33: U.S. Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 34: U.S. Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 35: U.S. Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 36: U.S. Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 37: Canada Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 38: Canada Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 39: Canada Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 40: Canada Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 41: Canada Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 42: Canada Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 43: Canada Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 44: Europe Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 45: Europe Liver Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
Figure 46: Europe Liver Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2025 to 2035
Figure 47: Europe Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 48: Europe Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 49: Europe Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 50: Europe Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 51: Europe Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 52: Europe Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 53: Germany Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 54: Germany Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 55: Germany Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 56: Germany Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 57: Germany Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 58: Germany Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 59: Germany Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 60: U.K. Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 61: U.K. Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 62: U.K. Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 63: U.K. Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 64: U.K. Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 65: U.K. Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 66: U.K. Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 67: France Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 68: France Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 69: France Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 70: France Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 71: France Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 72: France Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 73: France Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 74: Italy Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 75: Italy Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 76: Italy Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 77: Italy Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 78: Italy Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 79: Italy Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 80: Italy Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 81: Spain Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 82: Spain Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 83: Spain Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 84: Spain Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 85: Spain Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 86: Spain Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 87: Spain Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 88: Switzerland Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 89: Switzerland Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 90: Switzerland Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 91: Switzerland Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 92: Switzerland Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 93: Switzerland Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 94: Switzerland Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 95: The Netherlands Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 96: The Netherlands Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 97: The Netherlands Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 98: The Netherlands Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 99: The Netherlands Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 100: The Netherlands Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 101: The Netherlands Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 102: Rest of Europe Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 103: Rest of Europe Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 104: Rest of Europe Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 105: Rest of Europe Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 106: Rest of Europe Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 107: Rest of Europe Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 108: Rest of Europe Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 109: Asia Pacific Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 110: Asia Pacific Liver Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
Figure 111: Asia Pacific Liver Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2025 to 2035
Figure 112: Asia Pacific Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 113: Asia Pacific Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 114: Asia Pacific Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 115: Asia Pacific Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 116: Asia Pacific Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 117: Asia Pacific Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 118: China Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 119: China Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 120: China Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 121: China Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 122: China Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 123: China Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 124: China Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 125: India Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 126: India Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 127: India Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 128: India Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 129: India Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 130: India Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 131: India Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 132: Japan Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 133: Japan Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 134: Japan Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 135: Japan Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 136: Japan Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 137: Japan Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 138: Japan Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 139: South Korea Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 140: South Korea Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 141: South Korea Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 142: South Korea Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 143: South Korea Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 144: South Korea Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 145: South Korea Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 146: Australia & New Zealand Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 147: Australia & New Zealand Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 148: Australia & New Zealand Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 149: Australia & New Zealand Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 150: Australia & New Zealand Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 151: Australia & New Zealand Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 152: Australia & New Zealand Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 153: Rest of Asia Pacific Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 154: Rest of Asia Pacific Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 155: Rest of Asia Pacific Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 156: Rest of Asia Pacific Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 157: Rest of Asia Pacific Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 158: Rest of Asia Pacific Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 159: Rest of Asia Pacific Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 160: Latin America Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 161: Latin America Liver Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
Figure 162: Latin America Liver Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2025 to 2035
Figure 163: Latin America Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 164: Latin America Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 165: Latin America Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 166: Latin America Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 167: Latin America Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 168: Latin America Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 169: Brazil Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 170: Brazil Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 171: Brazil Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 172: Brazil Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 173: Brazil Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 174: Brazil Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 175: Brazil Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 176: Mexico Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 177: Mexico Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 178: Mexico Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 179: Mexico Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 180: Mexico Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 181: Mexico Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 182: Mexico Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 183: Argentina Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 184: Argentina Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 185: Argentina Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 186: Argentina Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 187: Argentina Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 188: Argentina Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 189: Argentina Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 190: Rest of Latin America Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 191: Rest of Latin America Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 192: Rest of Latin America Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 193: Rest of Latin America Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 194: Rest of Latin America Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 195: Rest of Latin America Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 196: Rest of Latin America Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 197: Middle East & Africa Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 198: Middle East & Africa Liver Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
Figure 199: Middle East & Africa Liver Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2025 to 2035
Figure 200: Middle East & Africa Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 201: Middle East & Africa Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 202: Middle East & Africa Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 203: Middle East & Africa Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 204: Middle East & Africa Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 205: Middle East & Africa Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 206: GCC Countries Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 207: GCC Countries Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 208: GCC Countries Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 209: GCC Countries Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 210: GCC Countries Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 211: GCC Countries Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 212: GCC Countries Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 213: South Africa Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 214: South Africa Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 215: South Africa Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 216: South Africa Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 217: South Africa Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 218: South Africa Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 219: South Africa Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 220: Rest of Middle East & Africa Liver Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 221: Rest of Middle East & Africa Liver Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 222: Rest of Middle East & Africa Liver Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 223: Rest of Middle East & Africa Liver Cancer Diagnostics Market Value Share Analysis, By Cancer Type, 2024 and 2035
Figure 224: Rest of Middle East & Africa Liver Cancer Diagnostics Market Attractiveness Analysis, By Cancer Type, 2025 to 2035
Figure 225: Rest of Middle East & Africa Liver Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 226: Rest of Middle East & Africa Liver Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035